Hide Board Information

Show Board Information

MERRILL LYNCH & CO INC 6.75% NTS 21/05/13 USD50000 50XP

Board Mod: Add me as mod

Asst Mods:

Last Post: 06/04/2012 2:03:26 AM

Board Marks: 0

Posts Today: 0

Board Views Today: 1

MERRILL LYNCH & CO INC 6.75% NTS 21/05/13 USD50000 (50XP) Stock Message Board

Find 50XP Recent News, 50XP Filings, 50XP Stock Quote, 50XP Stock Chart, 50XP Research & Opinions Below

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

Be the first to post on MERRILL LYNCH & CO INC 6.75% NTS 21/05/13 USD50000 50XP

Recent Articles

• Understanding Major Holdings Notification for Investors
• Macy’s, Inc. Reports Impressive Third Quarter Financial Performance
• Roots Canada Achieves Strong Q3 Financial Performance
• Investigation of Patterson Companies: Fair Value Concerns
• Palantir Launches Warp Speed Program to Boost Manufacturing
• Innovations in Psychiatry: Findings from Seaport Therapeutics
• New Resource Website by Chemical Insights for WUI Fire Safety
• Gameday Men's Health Launches Expanded Services in Canada
• Understanding Low Testosterone: Impact on Men's Moods
• ReposiTrak Expands Network with 50 New Diverse Suppliers
• OXIO Partners with AT&T to Transform Telecom Services
• Essential Security Tips for a Happy and Safe Holiday Season
• Ververica Enhances Global Impact Through Innovative Partnerships
• Empowering Parents: Navigating Youth Mental Health Together
• Seaport Therapeutics Showcases Phase 1 Progress of SPT-300
• Exciting Developments Coming with the 2025 Mitsubishi Outlander
• Wynn Resorts Enhances Investor Relations with New Leaders
• Revolutionizing Genetic Treatments: nChroma Bio Emerges Stronger
• Exploring the Future of Advanced Air Mobility with Eve and Signature
• Veradermics Secures $75 Million for Hair Loss Treatment Trial
• Surge in Demand for Non-Associated Cellulose Rheology Modifiers
• Natural Beta Carotene Market Forecast: 4.4% Growth Ahead
• Multiparameter Patient Monitoring Market Growth and Trends
• Mobix Labs Set for Fourth Quarter Earnings Call in December
• Collaboration to Boost Cancer Immunotherapy with PLEX Tech
• Evergold Corp. Reports Promising Antimony Drill Results
• Collaborative Carbon Capture Efforts from CarbonQuest and Carbfix
• Falco Resources Elects New Directors and Finalizes Debt Deals
• Adams Clinical Expands Psychiatry Research with New Partnership
• CareDx Teams Up with TC BioPharm for Innovative Clinical Trials
• Candel Therapeutics Reports Promising Phase 3 Results for CAN-2409
• Octapharma Enhances Supply Chain Efficiency with Kinaxis
• Boralex Secures $538 Million for Major Energy Storage Project
• IISc and Ittiam Systems Forge Partnership in AI Innovation
• Rafael Holdings Shows Resilience in Q1 Fiscal 2025 Results
• Enhancing Electronic Warfare: Pacific Defense's New AI Contract
• Simply Good Foods Prepares to Share Q1 Financial Insights
• Satellos Takes Significant Step in DMD Treatment with SAT-3247
• Monte Rosa's New Licensing Deal with Novartis: A Game Changer
• Bloomreach Commits to Community Service with Pledge 1% Initiative
• New Advances in Treating HR-positive Breast Cancer Revealed
• ExxonMobil's Vision for 2030: Driving Sustainable Growth
• Tilray Expands Festive THC Beverage Offerings with XMG and Mollo
• Bio-Path Holdings Advances BP1001-A for Diabetes and Obesity
• Mongolian Mining Corporation Joins OTCQX for Greater Reach
• Fiduciary Trust Company Welcomes Puneet Nevatia as COO
• Ocugen CEO Set to Discuss Innovations at Rare Disease Summit
• Strategic Partnership: ZEDRA and Gryphon Enhance Fund Solutions
• Cognyte Shows Strong Growth in Third Quarter FY 2025 Results
• Celcuity Reveals Promising Overall Survival Data from Gedatolisib Study